Amphastar Pharmaceuticals (AMPH) Receivables (2013 - 2026)

Amphastar Pharmaceuticals' Receivables history runs 14 years deep, the most recent figure standing at $147.8 million for Q1 2026.

• In Q1 2026, Receivables rose 2.08% year-over-year to $147.8 million; the TTM figure through Mar 2026 stood at $147.8 million (up 2.08% YoY), while the FY2025 annual figure was $143.6 million, up 5.18% from the prior year.
• Receivables was $147.8 million for Q1 2026 at Amphastar Pharmaceuticals, up from $143.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $147.8 million in Q1 2026 to a low of $73.2 million in Q1 2022.
• Historically, Receivables has averaged $119.0 million across 5 years, with a median of $131.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables fell 6.12% in 2022, then jumped 53.93% in 2023.
• A 5-year view of Receivables shows it stood at $89.2 million in 2022, then grew by 28.85% to $114.9 million in 2023, then climbed by 18.74% to $136.5 million in 2024, then grew by 5.18% to $143.6 million in 2025, then climbed by 2.99% to $147.8 million in 2026.
• The last three Receivables figures came in at $147.8 million (Q1 2026), $143.6 million (Q4 2025), and $146.8 million (Q3 2025), per Business Quant data.